[{"data":1,"prerenderedAt":167},["ShallowReactive",2],{"drug-cilostazol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":69,"warnings":79,"renal":80,"monitoring":81,"interactions":82,"review":83,"examples":86,"atc":92,"iran":94,"links":110,"populations":127,"usApproval":162},"cilostazol",1,{"fa":7,"en":8},"سیلوستازول","Cilostazol","blood",{"fa":11,"en":12},"مهارکننده فسفودی‌استراز III","Phosphodiesterase III inhibitor",[14],{"name":15,"market":16},"Pletal","US",[18,19,7],"pletal","پلتال",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"fda-cilostazol","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-100","100 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},100,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":57,"notes":60},"std","intermittent-claudication",{"fa":48,"en":49},"لنگش متناوب — ۱۰۰ mg دو بار در روز، ناشتا","Intermittent claudication — 100 mg twice daily, fasting",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":39,"dosesPerDay":56},2,[58],{"source":33,"section":59},"2.1",[61],{"text":62,"refs":65},{"fa":63,"en":64},"نیم ساعت پیش یا ۲ ساعت پس از صبحانه و شام. با مهارکننده‌های CYP3A4 یا CYP2C19 (کتوکونازول، اریترومایسین، دیلتیازم، امپرازول، فلوکونازول): ۵۰ mg دو بار. اگر پس از ۳ ماه بهتر نشد قطع.","30 min before or 2 h after breakfast and dinner. With CYP3A4 or CYP2C19 inhibitors (ketoconazole, erythromycin, diltiazem, omeprazole, fluconazole): 50 mg twice daily. Stop if no improvement after 3 months.",[66,67],{"source":33,"section":59},{"source":33,"section":68},"2.2",[70],{"id":71,"severity":72,"text":73,"refs":76},"ci","block",{"fa":74,"en":75},"نارسایی قلب با هر شدت؛ حساسیت.","Heart failure of any severity; hypersensitivity.",[77],{"source":33,"section":78},"4",[],[],[],[],{"status":84,"reviewer":85,"date":85},"unverified",null,[87],{"regimen":45,"formulation":36,"input":88,"expect":91},{"ageYears":89,"weightKg":90},65,75,{"perDose":39,"tabletsPerDoseRounded":5},[93],"B01AC23",{"status":95,"forms":96,"refs":105},"registered",[97,101],{"code":98,"en":99,"fa":100},"06453","CILOSTAZOL 100MG TAB","قرص سیلوستازول ۱۰۰ میلی‌گرم",{"code":102,"en":103,"fa":104},"07516","CILOSTAZOL 50MG TAB","قرص سیلوستازول ۵۰ میلی‌گرم",[106],{"source":107,"section":108,"url":109},"darooyab-generic","G-1597\u002FCilostazol","https:\u002F\u002Fwww.darooyab.ir\u002FG-1597\u002FCilostazol",[111,115,119,122,125],{"kind":112,"url":113,"label":114},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=077030","ANDA077030",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ceac1ae3-c343-28ca-c083-b748d21a15e6","FDA Cilostazol",{"kind":120,"url":121,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601038.html",{"kind":123,"url":124,"label":93},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC23",{"kind":126,"url":109,"label":8},"darooyab",{"pregnancy":128,"lactation":137,"pediatric":145,"geriatric":154},{"level":129,"text":130,"quote":133,"refs":134},"caution",{"fa":131,"en":132},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Teratogenic Effects Pregnancy Category C.",[135],{"source":33,"section":136},"8.1",{"level":129,"text":138,"quote":141,"refs":142},{"fa":139,"en":140},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Transfer of cilostazol into milk has been reported in rats.",[143],{"source":33,"section":144},"8.3",{"level":146,"text":147,"quote":150,"refs":151},"not-established",{"fa":148,"en":149},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of cilostazol in pediatric patients have not been established.",[152],{"source":33,"section":153},"8.4",{"level":129,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","…  reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be excluded.",[160],{"source":33,"section":161},"8.5",{"kind":163,"refs":164,"id":114},"ANDA",[165],{"source":33,"section":166},"SPL approval \u002F marketing category",1792111448607]